A practical reference on cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-06. Anything still debated is marked as such rather than presented as settled.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Graft copolymerization: The growing polystyrene chain reacts with a double bond of the polybutadiene. As a result, several polystyrene chains are attached to one polybutadiene. S represents in the figure the styrene repeat unit B the butadiene repeat unit. However, the middle block often does not consist of such depicted butane homo-polymer but of a styrene-butadiene co-polymer: SSSSSSSSSSSSSSSSSSSBBSBBSBSBBBBSBSSBBBSBSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS By using a statistical copolymer at this position, the polymer becomes less susceptible to cross-linking and flows better in the melt. For the production of SBS, the first styrene is homopolymerized via anionic copolymerization. Typically, an organometallic compound such as butyllithium is used as a catalyst. Butadiene is then added and after styrene again its polymerization. The catalyst remains active during the whole process (for which the used chemicals must be of high purity). The molecular weight distribution of the polymers is very low (polydispersity in the range of 1.05, the individual chains have thus very similar lengths). The length of the individual blocks can be adjusted by the ratio of catalyst to monomer. The size of the rubber sections, in turn, depends on the block length. The production of small structures (smaller than the wavelength of the light) ensure transparency. In contrast to PS-I, however, the block copolymer does not form any particles but has a lamellar structure.
==== United Kingdom ==== In the United Kingdom, preparations containing only dextropropoxyphene were discontinued in 2004. In 2007, the Medicines and Healthcare products Regulatory Agency removed the licence for co-proxamol, also called distalgesic. From then on in the UK, co-proxamol is only available on a named patient basis, for long-term chronic pain and only to those who have already been prescribed this medicine. Its withdrawal from the UK market is a result of concerns relating to its toxicity in overdose (even small overdoses can be fatal), and dangerous reaction with alcohol. Recreational use in the UK is uncommon. Many patients have been prescribed alternative combinations of drugs as a replacement. The motivation for the withdrawal of co-proxamol was the reduction in suicides and a key part of the agency's justification of its decision was based upon studies showing co-proxamol was no more effective than paracetamol alone in pain management. The co-proxamol preparations available in the UK contained a subtherapeutic dose of paracetamol, 325 mg per tablet. Patients were warned not to take more than eight tablets in one day, a total dose of 2600 mg paracetamol per day. Despite this reduced level, patients were still at a high risk of overdose; coproxamol was second only to tricyclic antidepressants as the most common prescription drugs used in overdose. Following the reduction in prescribing in 2005–2007, prior to its complete withdrawal, the number of deaths associated with the drug dropped significantly.
Brazilian literature dates back to the 16th century, to the writings of the first Portuguese explorers in Brazil, such as Pero Vaz de Caminha, filled with descriptions of fauna, flora and commentary about the indigenous population that fascinated European readers. Brazil produced significant works in Romanticism—novelists such as Joaquim Manuel de Macedo and José de Alencar wrote novels about love and pain. Alencar, in his long career, also treated indigenous people as heroes in the Indigenist novels O Guarani, Iracema and Ubirajara. Machado de Assis, one of his contemporaries, wrote in virtually all genres and continues to gain international prestige from critics worldwide. Brazilian Modernism, evidenced by the Modern Art Week in 1922, was concerned with a nationalist avant-garde literature, while Post-Modernism brought a generation of distinct poets such as João Cabral de Melo Neto, Carlos Drummond de Andrade, Vinicius de Moraes, Cora Coralina, Graciliano Ramos, Cecília Meireles, and internationally known writers dealing with universal and regional subjects such as Jorge Amado, João Guimarães Rosa, Clarice Lispector and Manuel Bandeira. Brazil's most significant literary award is the Camões Prize, which it shares with the rest of the Portuguese-speaking world. As of 2016, Brazil has eleven recipients of the prize. Brazil also holds its own literary academy, the Brazilian Academy of Letters, a non-profit cultural organization aimed at perpetuating the care of the national language and literature.
Sources: en.wikipedia.org
==== Development of oral antivirals ==== In November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as Paxlovid. In January 2022, the Pfizer CEO Albert Bourla confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company, Novasep. He also said the COVID vaccine was "safe and efficient" for children. In May 2022, reports emerged of patients experiencing "rebound" symptoms after completing a five-day course of Paxlovid. The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations. U.S. President Joe Biden and Dr. Anthony Fauci were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.
== Political organization == Lad served as General Secretary of the Karnataka Pradesh Congress Committee (KPCC) and was given responsibility for Raichur district organization during his earlier period in Congress politics. In January 2023, the Congress appointed Lad as a co-chairman in the party's Karnataka Assembly election campaign committee, with responsibility for the Belagavi division. He also participated in Congress's Bharat Jodo Yatra activities in Karnataka in 2022. Lad started his political career as a counsellor from Sandur taluk. He had very little success in Pattana panchayat elections, where he lost marginally in his first election. He went on to win both seats he contested in the following election, contributing to his party gaining the majority during that period. Lad contested the MLA election against a strong contender from the Congress Party. He represented the Janata Dal (Secular) party and was the youngest MLA (aged 29), along with the first person from his party to win Sandur constituency; the election was won with a record margin. Lad was part of the government formation under H. D. Kumaraswamy, ex-chief minister of the Karnataka state. In the 2008 Karnataka Assembly elections, he won the Kalaghatgi constituency in the Dharwad district. He currently is an active member and represents Indian National Congress. In the 2013 Karnataka state assembly election, Santosh Lad won with a margin of over 45,000 votes, to win consecutively for the second time from Kalaghatgi and third time overall. Congress secured an absolute majority to form the government.
By the spring of 1917, the War was dragging on towards its fourth year, and Zita's brother Prince Sixtus of Bourbon-Parma, a serving officer in the Belgian Army, was a main mover behind a plan for Austria-Hungary to make a separate peace with France. Charles initiated contact with Sixtus through contacts in neutral Switzerland, and Zita wrote a letter inviting him to Vienna. Zita's mother, Maria Antonia, delivered the letter in person. Sixtus arrived with conditions for talks which had been agreed with the French – the restoration to France of Alsace-Lorraine (annexed by Germany after the Franco-Prussian War in 1870); restoration of the independence of Belgium; independence for the kingdom of Serbia; and the handover of Constantinople to Russia. Charles agreed, in principle, to the first three points and wrote a letter to Sixtus dated 25 March 1917 which sent "the secret and unofficial message" to the President of France that "I will use all means and all my personal influence". This attempt at dynastic diplomacy eventually foundered. Germany refused to negotiate over Alsace-Lorraine, and, seeing a Russian collapse on the horizon, was loath to give up the war. Sixtus continued his efforts, even meeting David Lloyd George in London about Italy's territorial demands on Austria in the 1915 Treaty of London, but the Prime Minister could not persuade his generals that Britain should make peace with Austria. Zita managed a personal achievement during this time by stopping the German plans to send airplanes to bomb the home of the King and Queen of Belgium on their name days.
Sources: en.wikipedia.org
Animals that characterize the Appalachian forests include five species of tree squirrels. The most commonly seen is the low to moderate elevation eastern gray squirrel (Sciurus carolinensis). Occupying similar habitat is the slightly larger fox squirrel (Sciurus niger) and the much smaller southern flying squirrel (Glaucomys volans). More characteristic of cooler northern and high elevation habitat is the red squirrel (Tamiasciurus hudsonicus), whereas the Appalachian northern flying squirrel (Glaucomys sabrinus fuscus), which closely resembles the southern flying squirrel, is confined to northern hardwood and spruce–fir forests. As familiar as squirrels are the eastern cottontail rabbit (Silvilagus floridanus) and the white-tailed deer (Odocoileus virginianus). The latter in particular has greatly increased in abundance as a result of the extirpation of the eastern wolf (Canis lupus lycaon) and the North American cougar. This has led to the overgrazing and browsing of many plants of the Appalachian forests, as well as destruction of agricultural crops. Other deer include the moose (Alces alces ), found only in the north, and the elk (Cervus canadensis), which, although once extirpated, is now making a comeback, through transplantation, in the southern and central Appalachians. In Quebec, the Chic-Chocs host the only population of reindeer (Rangifer tarandus) south of the St. Lawrence River. An additional species that is common in the north but extends its range southward at high elevations to Virginia and West Virginia is the varying or snowshoe hare (Lepus americanus).
== Process == After the purchase of a breast milk keepsake design the consumer sends their breast milk to the creator so the process can begin. Each creator likely uses a different trade process. In some methods it is believed that solvents or chemicals are added to assist the preservation. Other methods may include dehydrating, freeze drying, cooking down, or mixing breast milk with other media. Once the preserved breast milk and resin mixture is ready, it is carefully poured into molds, or a bezel setting, to create the desired stone shape. The molds can be customized to create various designs like those found in traditional jewelry design, hearts, flowers, or abstract shapes. The mixture is left to cure and harden, which can take several hours or even days depending on the specific resin used.
{\displaystyle {\begin{array}{lll}M({\ce {H2}})&=2\times 1.00794(7)\times M_{\mathrm {u} }&=2.01588(14){\text{ g/mol}}\\M({\ce {N2}})&=2\times 14.0067(2)\times M_{\mathrm {u} }&=28.0134(4){\text{ g/mol}}\\M({\ce {O2}})&=2\times 15.9994(3)\times M_{\mathrm {u} }&=31.9988(6){\text{ g/mol}}\\M({\ce {S8}})&=8\times 32.065(5)\times M_{\mathrm {u} }&=256.52(4){\text{ g/mol}}\\M({\ce {Cl2}})&=2\times 35.453(2)\times M_{\mathrm {u} }&=70.906(4){\text{ g/mol}}\end{array}}}
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.